Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1150 of 2026 entries
View as:

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05047250 Org: User:
Start: 06/14/22 End: 06/30/28 Due: 06/30/29

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06934044 Org: User:
Start: 05/13/25 End: 05/08/28 Due: 05/08/29

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

Phase: N/A Priority: Normal
NCT ID: NCT06680817 Org: User:
Start: 02/05/25 End: 06/15/28 Due: 06/15/29

A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT06903065 Org: User:
Start: 04/14/25 End: 09/30/26 Due: 09/30/27

A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01670045 Org: User:
Start: 03/31/12 End: 06/30/14 Due: 06/30/15

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

Phase: N/A Priority: Normal
NCT ID: NCT01903993 Org: User:
Start: 08/06/13 End: 09/06/18 Due: 09/06/19

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT01871805 Org: User:
Start: 09/30/13 End: 08/31/17 Due: 08/31/18

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

Phase: N/A Priority: Normal
NCT ID: NCT02453256 Org: User:
Start: 11/20/15 End: 02/04/19 Due: 02/04/20

APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin

Phase: N/A Priority: Normal
NCT ID: NCT02850289 Org: User:
Start: 04/30/06 End: 10/31/08 Due: 10/31/09

A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01615393 Org: User:
Start: 06/30/11 End: 10/31/11 Due: 10/31/12

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)

Phase: N/A Priority: Normal
NCT ID: NCT01309282 Org: User:
Start: 07/31/10 End: 08/31/13 Due: 08/31/14

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03292172 Org: User:
Start: 11/08/17 End: 02/26/19 Due: 02/26/20

A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01476267 Org: User:
Start: 10/31/11 End: 11/30/11 Due: 11/30/12

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Participants With Influenza

Phase: N/A Priority: Normal
NCT ID: NCT06094010 Org: User:
Start: 11/22/23 End: 06/30/27 Due: 06/30/28

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Phase: N/A Priority: Normal
NCT ID: NCT03823287 Org: User:
Start: 02/19/19 End: 01/18/22 Due: 01/18/23

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04285567 Org: User:
Start: 05/28/20 End: 07/31/26 Due: 07/31/27

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Phase: N/A Priority: Normal
NCT ID: NCT00869661 Org: User:
Start: 02/28/01 End: 02/29/12 Due: 02/28/13

A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.

Phase: N/A Priority: Normal
NCT ID: NCT00503113 Org: User:
Start: 07/31/07 End: 04/30/10 Due: 04/30/11

A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT04341259 Org: User:
Start: 11/03/20 End: 04/06/23 Due: 04/06/24

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With Tocilizumab (RoActemra/Actemra)

Phase: N/A Priority: Normal
NCT ID: NCT01613378 Org: User:
Start: 02/29/12 End: 10/31/14 Due: 10/31/15

An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)

Phase: N/A Priority: Normal
NCT ID: NCT01277120 Org: User:
Start: 04/30/10 End: 04/30/16 Due: 04/30/17

Observational Safety Study of Rituximab in Patients Diagnosed With Rheumatoid Arthritis (RA) Who Did Not Respond Adequately to TNF-alpha Blocker

Phase: N/A Priority: Normal
NCT ID: NCT02322801 Org: User:
Start: 03/31/09 End: 11/30/11 Due: 11/30/12

A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00486759 Org: User:
Start: 07/26/07 End: 11/30/11 Due: 11/30/12

Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00112918 Org: User:
Start: 12/31/04 End: 06/30/12 Due: 06/30/13

Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

Phase: N/A Priority: Normal
NCT ID: NCT02630563 Org: User:
Start: 05/31/03 End: 01/31/05 Due: 01/31/06